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Background: The routes to diagnosis and the time intervals along the diagnostic pathway affect cancer 
outcomes. Some data on routes to diagnosis and milestone dates can be extracted from registries or 
databases. When this data is incomplete, inaccurate or non-existing, other data sources are needed. This 
study investigates the agreement between multiple data sources on routes to diagnosis and milestone dates 
of cancer pathway.  
 
Methods: Information on routes to diagnosis and milestone dates  were compared across four data sources 
(cancer patients, general practitioners, cancer specialists and registries) for breast, colorectal, lung and 
ovarian cancers across the UK, Scandinavia, Canada and Australia. Agreement on routes to diagnosis and 
milestone dates was assessed by Kappa and AC1 coefficients and Lin’s concordance correlation coefficient 
(CCC). 
 
Results: 4,502 patients were included in the analysis of routes to diagnosis. The agreement was almost 
perfect (kappa=0.15-0.88, AC1=0.86-0.91) for breast cancer, substantial to almost perfect (kappa=0.07-0.86, 
AC1=0.74-0.93) for colorectal and ovarian cancers, and substantial (kappa=0.09-0.11, AC1=0.65-0.74) for lung 
cancer. 2,287 patients were included in the analysis of milestone dates. The agreement was adequate for all 
cancer types (CCC=0.88-0.99); highest agreement was seen for date of diagnosis (CCC=0.94-0.99). 
 
Conclusion: We found a reasonable agreement between patient/physician questionnaires and registry data 
for routes to diagnosis and milestone dates. The agreement on routes to diagnosis was generally higher for 
breast cancer than for colorectal, ovarian and lung cancers. Lower agreement was seen on date of first 
presentation to primary care and date of treatment initiation compared to date of diagnosis.  
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Cancer outcomes are influenced by the route to diagnosis and the time intervals in the diagnostic pathway 
(e.g. the interval between first presentation to healthcare and diagnosis).  Patients diagnosed with cancer 
through emergency presentation have poorer clinical and patient-reported outcomes than patients 
diagnosed through non-emergency presentation or screening [1]. Advanced staging at diagnosis and 
increased mortality have been associated with the time to diagnosis, and some cancers have been shown to 
progress during the interval between diagnosis and treatment [2],[3],[4],[5].  
 
Information on the routes to diagnosis and milestone dates can sometimes be established from registries, 
which are generally accepted as the most accurate sources of information [6]. However, other data sources 
may be required when registry data are not available. Detailed information about the pre-diagnostic phase 
is particularly important and may be obtained from questionnaires completed by patients and physicians. 
 
The growing interest in research on routes to diagnosis and time delays brings a need to establish the level 
of agreement between registry data and questionnaire instruments on this type of data. Moreover, it is 
important to explore whether combining data from multiple sources can be used to map the routes to 
diagnosis and measure the time intervals in the diagnostic pathway.  
 
Existing studies on concordance of routes to diagnosis and milestone dates have compared data from 
various data sources, but these studies have primarily focussed on a single combination of data sources 
(e.g. self-report and medical record), a single object (e.g. date of diagnosis) or a single disease (e.g. breast 
cancer) [7],[8],[9],[10],[11],[12]. To our knowledge, no previous studies have explored the agreement 
between several data sources on several objects and diseases across several countries. 
 
The International Cancer Benchmarking Partnership (ICBP) explores cancer outcomes variation between 
comparable countries [13],[14],[15]. Module 4 (ICBP4) was established to  describe cancer pathways and 
investigate the association between the diagnostic time intervals and outcomes of breast, colorectal, lung 
and ovarian cancer in six countries [16]. This ICBP4 study aims to investigate the agreement on routes to 
diagnosis and milestone dates in the cancer diagnostic pathway by comparing data from patients, general 
practitioners (GPs), cancer specialists (SPs) and cancer registries.  
 
2. Methods 
2.1 Setting and population  
This ICBP4 population-based cohort study included patients with newly diagnosed breast, colorectal, lung or 
ovarian cancer recorded in cancer- and hospital-based registries in 10 jurisdictions across the UK (Wales, 
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England, Scotland, Northern Ireland), Denmark, Sweden, Norway, Canada (Ontario, Manitoba) and Australia 
(Victoria) during 2013-2015. Patients below age 40 years and with a history of a cancer in the same organ or 
two or more primary cancers were ineligible.  
 
2.2 Data collection 
A questionnaire was sent to eligible patients, their GP and their main SP. Three strategies for contacting 
patients were used. Participating registries (a) forwarded the patient’s details to the local ICBP4 team, who 
sent the questionnaire directly to the patient; (b) sent a letter to the relevant GP with a request to forward 
a pre-addressed envelope to the patient or; (c) the questionnaire was directly sent to the patient after 
contacting the patient’s treating clinician to confirm study eligibility. The material provided a detailed 
description of routes to diagnosis, milestone dates, symptoms and informed consent. The teams obtained 
information on screening status and date of diagnosis from cancer registries and clinical databases.  
 
Patients with missing information on gender, age, date of consent and diagnosis were excluded. To reduce 
recall bias, patients completing the questionnaire more than nine months after diagnosis were excluded. 
Additionally, patients from Sweden and Norway were excluded from the analysis, as only patients completed 
the survey in Sweden, whereas Norway provided no registry data. The data collection and management has 
been described in further detail elsewhere [16]. 
 
2.3 Routes to diagnosis 
We focused on screening, symptomatic presentation and other presentation to the healthcare system as 
reported by patient and GP and recorded in the registry. The SP was not asked about routes to diagnosis. 
 
Screening 
Screening was an option for breast and colorectal cancer patients only, as no national screening programmes 
existed for lung and ovarian cancers at the time of the patient recruitment. In some jurisdictions, patients 
could be offered screening as part of an organised programme, or screening could be requested by their GP. 
The latter test was not used in the agreement analysis.  
 
Symptomatic route 
Information about symptomatic presentation was available from patient and GP questionnaires. 
Symptomatic presentation was defined as to include patients with any reported symptoms or presented 
through ‘visit to GP’, ‘visit to GP and accident and emergency department (A&E)’, ‘A&E’ or ‘visit to doctor for 





The data on other routes was available from patient and GP questionnaires. 
 
2.4 Milestone dates 
We focused on three selected milestone dates: date of first cancer-related visit to primary care, date of 
diagnosis and date of treatment initiation. 
 
Date of first visit 
The patients and GPs were asked about the exact date of the first visit to primary care for a specific cancer. 
Breast and colorectal cancer patients were excluded from the analysis if their route to diagnosis was 
screening. 
 
Date of diagnosis 
Patient questionnaire and registry records included single items on the date of cancer diagnosis, whereas the 
date of diagnosis in GP and SP questionnaires was defined as: date of histological confirmation, date of 
biopsy, date of results of investigation, date of hospital admission, date of confirmation by multidisciplinary 
team, date when “patient was told” or other date of diagnosis (in declining order of priority).  
 
Date of treatment 
Date of treatment was collected from patient and SP questionnaires. For patient data, the date was defined 
as the earliest date of either surgery, chemotherapy, radiology or other treatment.  
 
If the difference between two dates for the same milestone was more than one year when reported by 
different sources, such milestone was considered a potential outlier and excluded from the analysis. 
 
2.5 Statistical analyses 
The agreement for nominal variables on routes to diagnosis was assessed by chance-corrected agreement in 
the form of kappa coefficients [17] and Gwet’s AC1 [18].  Cohen’s kappa statistics is widely used to compute 
agreement between raters on nominally scaled data. However, it is known to be affected by an unbalanced 
prevalence of the trait, i.e. in a situation where a large proportion of ratings is either positive or negative,  
kappa may then yield a low value despite high overall percentage agreement [19]. We used AC1 as an 
alternative agreement coefficient to remediate this issue. Agreement measured by kappa and AC1 was 
interpreted as: poor (below 0), slight (0–0.2), fair (0.2–0.4), moderate (0.4–0.6), substantial (0.6-0.8) and 




The difference between dates could be approximated as following a normal distribution. The agreement for 
dates was measured by Lin’s concordance correlation coefficient (CCC) [21]. We interpreted agreement 
measured by CCC as: poor (below 0.4), moderate (0.4-0.7) and good (above 0.7) [22].  
 
The analysis was based on the combined dataset across all jurisdictions and was performed for each type of 
cancer and for the total dataset. The complete-case approach was used in the analyses. Several sensitivity 
analyses tested the robustness of the results. Statistical analyses were carried out in Stata, version 15. 
 
3. Results 
The flow of patients and the exclusion criteria are outlined in Fig. 1. A total of 4,502 (57%) fulfilled the 
inclusion criteria for the analyses of routes to diagnosis and 2,287 (29%) patients for the analyses of dates.  
 
While the gender and age distribution of included patients were comparable to that of identified patients, 
included patients were more likely to be women and aged 60-69 years. Included patients were more likely 
to have less advanced stage than identified patients and therefore more likely to be alive one year after 
diagnosis (Table A.1 in Appendix A).  
 
Included patients with breast or ovarian cancer were generally younger and had less comorbidity (Table 1). 
Slightly more than half of the patients with colorectal or lung cancer were men. The clinical features were 
similar for each jurisdiction, but the number of Ontario residents with lung or ovarian cancer used in the 
analysis of dates was low (Table A.2 in Appendix A). 
 
3.1 Agreement on routes to diagnosis 
Approximately 45% of breast cancers were detected by screening, 53% by symptomatic presentation and 5% 
by other routes (Table 2). Approximately 20% of colorectal cancers were detected by screening, 73% by 
symptomatic presentation and 11% by other routes.  Some patients reported multiple routes to diagnosis. 
 
The agreement on screening route was almost perfect (kappa ≥ 0.86 for breast cancer; overall agreement ≥ 
0.90, AC1 ≥ 0.85 for colorectal cancer) (Table 3). The agreement on symptomatic presentation was almost 
perfect for breast and ovarian cancers (kappa = 0.88 for breast cancer; overall agreement = 86%, AC1 = 0.84 
for ovarian cancer) and substantial for colorectal and lung cancers (overall agreement ≥ 80%, AC1 = 0.74). 
The agreement on other routes was high for breast cancer (overall agreement = 92%, AC1 = 0.91) and lower 
for the other three types of cancer (overall agreement ranged from 74% and AC1 from 0.65 for lung cancer 




In case of substantial discrepancy between kappa and AC1 coefficients, the result was interpreted as a good 
agreement if overall agreement and AC1 was high despite low kappa. In this situation, the proportion of 
patients using a specific route to diagnosis was either very low or very high, and the kappa coefficient was 
thus considered to be artificially low due to the unbalanced trait prevalence [19],[18]. 
 
3.2 Agreement on milestone dates 
Adequate agreement was achieved across all data sources for all milestone dates when the four types of 
cancer were assessed together (CCC = 0.92 for date of first presentation to primary care; 0.96 ≤ CCC ≤ 0.98 




ELIGIBLE: Patients aged 40 years or more; alive; with a first-time diagnosis of newly 
diagnosed breast, colorectal, lung or ovarian cancer in eight jurisdictions across 
Wales, England, Scotland, Northern Ireland, Denmark, Canada (Ontario, Manitoba) 
and Australia (Victoria); without prior history of cancer of the same organ or two or 
more primary cancers. 
N =42,458 
RESPONDENTS: Patients who returned a valid questionnaire (% of contacted patients). 
N = 10,441 (33.4%) 
(a) Analysis of routes to diagnosis 
INCLUDED PATIENTS: proportion of study population 
N =4,502 (56.8%) 
   
No response: 20,811 (66.6%) 
 
At least one 
missing route  
to diagnosis 
3,431 




STUDY POPULATION:Respondents not sampled for local purposes 
(% of respondents). 
N =7,933 (76.0%) 
Exclusion (total): 2,508 (24.0%) 
- Ineligible 195 (1.9%) 
- Extra sample for local purpose 1,424 (13.6%) 
- Other reasons 889 (8.5%) 
 
CONTACTED: Patients mailed a questionnaire (% of eligible patients). 
N = 31,252 (73.6%) 
Not contacted: 11,206 (26.4%) 
(e.g. due to death, another address, 
terminal illness, language difficulties)   
   
 889 (8.5%) 
 
 
(b) Analysis of milestone dates 
INCLUDED PATIENTS: proportion of study population 
N =2,287 (28.8%) 
Outliers                       256 (3.2%)    
 
At least one  
missing date             5,390 (67.9%) 
Data sources: proportion of included 
Patient/GP surveys: n=2,287 (100%) 
   Breast: n=1,008; Colorectal: n=664; Lung: n=360; Ovarian: n=255   
Specialist surveys: n=1,523 (66.6%)* 
   Breast: n=646; Colorectal: n=451; Lung: n=232; Ovarian: n=194   
Registry records: n=2,233 (97.6%) 
   Breast: n=1,008; Colorectal: n=664; Lung: n=306**; Ovarian: n=255  
 
Patient/GP surveys for symptomatic patients: n= 1,632 (100%) 
   Breast: n=574; Colorectal: n=473; Lung: n=339; Ovarian: n=246  
  
Data sources: proportion of included 
Patient/GP surveys: n=4,502 (100%) 
    Breast: n=1,573; Colorectal: n=1401; Lung: n=939; Ovarian: n=589 
Registry records: n=2,304 (77.5%)* 
  Breast: n=1,413**; Colorectal: n=891+; Lung: n=0; Ovarian: n=0 
 
*proportion of included for breast and colorectal cancers  
**No data from Ontario 
+No data from Ontario, Denmark and Victoria 
*No data from Manitoba and Northern Ireland  
**No data from Denmark 
 
Fig. 1.  Flowchart of patients included in the analysis on (a) routes to diagnosis and (b) milestone dates. 
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Table 1. Basic characteristics of patients included in the analyses of routes to diagnosis (top) and milestone 
dates (bottom) (n and % if nothing else stated) 
 




Breast cancer Colorectal cancer Lung cancer Ovarian cancer Total 
(N=1573) (N=1413) (N=939) (N=589) (N=4502) 
Age (years), Median (IQI) 62 (53,70) 69 (62,76) 69 (64,75) 63 (55,71) 66 (58,74) 
Gender, Male 
  among colorectal and lung 
cancer patients 
 - 816 (58) 495 (53)  - 1311 (56) 
Comorbidity1           
None 1098 (70) 769 (55) 355 (38) 408 (69) 2,630 (58) 
Medium 454 (29) 599 (43) 532 (57) 176 (30) 1,761 (39) 
High 11 (1) 31 (2) 52 (5) 5 (1) 99 (2) 
Missing  10 (1) 2 (1) 0 (0) 0 (0) 12 (1) 
 




Breast cancer Colorectal cancer Lung cancer Ovarian cancer Total 
(N=1008) (N=664) (N=360) (N=255) (N=2287) 
Age (years), Median (IQI) 62 (52,69) 69 (62,76) 68 (64,75) 63 (55,70) 65 (57,73) 
Gender, Male  
 among colorectal and lung 
cancer patients 
 - 400 (60) 182 (51)  - 582 (57) 
Comorbidity1           
None 708 (70) 360 (54) 151 (42) 183 (72) 1402 (61) 
Medium 287 (28) 292 (44) 194 (54) 71 (28) 844 (37) 
High 10 (1) 12 (2) 15 (4) 1 (1) 38 (2) 
Missing  3 (1) 0 (0) 0 (0) 0 (0) 3 (1) 
1Comorbidity coded as none (none reported), medium (1-2 reported) and high (3+ reported) 














Table 2. Cancer patients’ routes to diagnosis expressed as proportions according to screening, symptomatic 




Proportion of cases with  
screening route (95% CI) 
Proportion of cases with 
symptomatic route (95% CI) 
 Proportion of cases with 
other route (95% CI) 
Breast cancer      
Patient (n=1573) 0.45 (0.42-0.47) 0.52 (0.50-0.54) 0.07 (0.06-0.08) 
GP (n=1573) 0.44 (0.41-0.46) 0.54 (0.52-0.56) 0.03 (0.02-0.04) 
Registry (n=1413) 0.44 (0.41-0.46) n/a n/a 
Colorectal cancer        
Patient (n=1401)    0.24 (0.22-0.27) * 0.71 (0.69-0.73) 0.12 (0.10-0.14) 
GP (n=1401) 0.17 (0.15-0.19) 0.75 (0.72-0.77) 0.10 (0.08-0.11) 
Registry (n=891) 0.22 (0.19-0.25) n/a n/a 
Lung cancer      
Patient (n=939) n/a 0.91 (0.89-0.92) 0.15 (0.13-0.18) 
GP (n=939) n/a 0.84 (0.81-0.86) 0.18 (0.16-0.21) 
Ovarian cancer     
Patient (n=589) n/a 0.91 (0.89-0.93) 0.13 (0.10-0.16) 
GP (n=589) n/a 0.92 (0.89-0.94)     0.11 (0.09-0.14) 
*n=1268 due to exclusion of Manitoba as it was unknown whether patients reported screening programme or test 
organised by GP 





Table 3. Agreement between different data sources to report if a cancer case was presented through 




Data sources Overall agreement 
(%) 
Kappa (95%CI) AC1 (95%CI) 
Breast cancer         
Screening 
Patient vs GP (n=1573) 93 0.86 (0.84,0.89) 0.86 (0.84,0.89) 
Registry vs Patient (n=1413) 93 0.86 (0.84,0.89) 0.87 (0.84,0.89) 
Registry vs GP (n=1413) 94 0.88 (0.86,0.91) 0.89 (0.87,0.91) 
     
Symptomatic Patient vs GP (n=1573) 94 0.88 (0.86,0.90) 0.88 (0.86,0.90) 
     
Other Patient vs GP (n=1573) 92 0.15 (0.07,0.24) 0.91 (0.89,0.93) 
Colorectal cancer         
Screening 
Patient vs GP (n=1268) 90 0.71 (0.66,0.76) 0.85 (0.83,0.88) 
Registry vs Patient (n=758) 93 0.82 (0.77,0.86) 0.88 (0.85,0.91) 
Registry vs GP (n=891) 95 0.86 (0.82,0.90) 0.93 (0.91,0.95)      
Symptomatic Patient vs GP (n=1401) 84 0.61 (0.56,0.65)  0.74 (0.71,0.78)      
Other Patient vs GP (n=1401) 83 0.09 (0.03,0.15) 0.78 (0.75,0.81) 
Lung cancer         
Symptomatic Patient vs GP (n=939) 80 0.11 (0.04,0.19) 0.74 (0.70,0.78)      
Other Patient vs GP (n=939) 74 0.09 (0.02,0.16) 0.65 (0.60,0.69) 
Ovarian cancer         
Symptomatic Patient vs GP (n=596) 86 0.12 (0.01,0.23) 0.84 (0.80,0.88)      
Other Patient vs GP (n=596) 80 0.07 (-0.02,0.16) 0.75 (0.70,0.80) 
Abbreviations: CI: confidence interval, GP: general practitioner 
 
Table 4. Mean difference (in days), proportions of agreement and concordance correlation coefficient (CCC) 
for dates of first visit to primary care, diagnosis and treatment, for each type of cancer and all cancers 










above  1 
week (%) 
CCC (95% CI) 
Breast cancer             
First visit to PC* GP vs Patient (n=574)  -5.6 44 24 32 0.95 (0.94,0.95)        
Diagnosis 
GP vs Patient (n=1008)  1.9 26 37 37 0.97 (0.96,0.97) 
Registry vs Patient (n=1008) -4.1 21 39 41 0.98 (0.98,0.98) 
Registry vs GP (n=1008) -6.0 27 41 32 0.98 (0.98,0.98) 
SP vs Registry (n=646) 5.0 16 61 22 0.98 (0.98,0.98) 
SP  vs Patient  (n=646) 0.6 17 50 33 0.95 (0.94,0.96) 
       
Treatment SP  and Patient (n=646) 4.6 61 16 23 0.88 (0.86,0.90) 
Colorectal cancer             
First visit to PC* GP vs Patient (n=473)  -2.4 25 20 55 0.89 (0.87,0.91 )        
Diagnosis 
GP vs Patient (n=664)  2.2 18 29 53 0.95 (0.95,0.96) 
Registry  vs Patient (n=664) -3.8 22 28 50 0.98 (0.98,0.98) 
Registry vs GP (n=664) -6.0 28 27 45 0.97 (0.96,0.97) 
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SP vs Registry (n=451) 7.1 18 53 30 0.95 (0.94,0.96) 
SP vs Patient  (n=451) 2.9 10 43 47 0.95 (0.94,0.96) 
       
Treatment SP  vs Patient (n=451) 4.0 58 18 24 0.89 (0.87,0.91) 
Lung cancer             
First visit to PC* GP vs Patient (n=339)  1.8 19 19 62 0.91 (0.89,0.93 ) 
       
Diagnosis 
GP vs Patient (n=360)  10.9 12 21 66 0.96 (0.95,0.97) 
Registry vs Patient (n=306) 5.9 6 26 68 0.98 (0.97,0.98) 
Registry vs GP (n=306) -7.2 23 28 49 0.97 (0.97,0.98) 
SP vs Registry (n=178) 11.9 17 37 46 0.95 (0.94,0.97) 
SP vs Patient  (n=232) 10.3 9 30 61 0.94 (0.93,0.96) 
       
Treatment SP vs Patient (n=232) 2.7 47 24 29 0.96 (0.95,0.97) 
Ovarian cancer             
First visit to PC* GP vs Patient (n=246)  6.4 35 18 48 0.91 (0.89,0.93) 
       
Diagnosis 
GP vs Patient (n=255)  10.0 9 27 64 0.97 (0.96,0.97) 
Registry vs Patient (n=255) 1.3 7 25 67 0.98 (0.97,0.98) 
Registry vs GP (n=255) -8.7 28 23 49 0.97 (0.97,0.98) 
SP vs Registry (n=194) 7.5 28 27 44 0.99 (0.98,0.99) 
SP  vs Patient  (n=194) 5.5 7 30 63 0.98 (0.98,0.98) 
       
Treatment SP  vs Patient (n=194) 8.1 57 17 26 0.93 (0.91,0.95) 
All cancers             
First visit to PC* GP vs Patient (n=1632)  -1.3 32 21 47 0.92 (0.91,0.92)        
Diagnosis 
GP vs Patient (n=2287)  4.3 19 31 50 0.96 (0.96,0.97) 
Registry  vs Patient (n=2233) -2.0 18 32 50 0.98 (0.98,0.98) 
Registry vs GP (n=2233) -6.5 27 33 40 0.98 (0.97,0.98) 
SP vs Registry (n=1469) 6.8 18 51 31 0.97 (0.97,0.97) 
SP  vs Patient  (n=1523) 3.4 12 43 45 0.96 (0.95,0.96) 
       
Treatment SP  vs Patient (n=1523) 4.6 57 18 25 0.90 (0.89,0.91) 
*only for symptomatic patients 
Abbreviations: CI: confidence interval, GP: general practitioner, PC: primary care, SP: cancer specialist  
 
disease, the agreement was still reasonable. CCC for date of first presentation ranged from 0.89 for colorectal 
cancer to 0.95 for breast cancer. CCC for date of treatment was about 0.88 for breast and colorectal cancers 
and above 0.9 for the other two diseases. CCC for date of diagnosis was homogenous across all four cancer 
types, ranging from 0.94 to 0.99. The mean difference ranged from 0.6 days for diagnosis date of breast 
cancer between SP and patient to 12 days for diagnosis date of lung cancer between SP and registry.  
 
3.3 Sensitivity analyses  
The sensitivity analyses, which investigated the implications of including patients with missing information in 
at least one data source for routes to diagnosis or milestone date, displayed similar findings as the main 
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analysis (Tables A.3-A.4 in Appendix A). And the basic characteristics of excluded and included patients were 
similar (Table A.5 in Appendix A). 
 
4. Discussion 
4.1 Key findings 
The present study assessed the agreement on routes to diagnosis and milestone dates in the diagnostic 
pathway reported by cancer patients, physicians and cancer registries in several countries. We found almost 
perfect agreement on routes to diagnosis (screening, symptomatic presentation and other presentation) for 
breast cancer across all explored data sources. However, the agreement was lower for colorectal, lung and 
ovarian cancers, ranging from substantial to almost perfect. The lowest level of agreement was seen for lung 
cancer. A possible explanation for the higher level of agreement in breast cancer is that the diagnostic 
pathways for this type of cancer may be relatively straightforward; by comparison, symptoms are typically 
vague in colorectal, lung and ovarian cancers, leading to more convoluted pathways. For example, a survey 
of patients with newly diagnosed ovarian cancer found that bloating and increased abdominal size were 
reported three to four times more often than documented in primary-care records [23].  
 
We found good agreement on milestone dates across all data sources and all types of dates. The agreement 
was highest for date of diagnosis, with almost no variation across different combinations of data sources. 
Lower agreement was seen for date of first presentation to primary care and date of treatment initiation 
across all four types of cancers. 
 
4.2 Comparison of findings with existing literature 
Some studies have questioned the quality of self-reported data in cancer research. A Canadian study [9] 
showed low agreement between self-reported history and physician’s records on less invasive colorectal 
cancer screening tests. However, the study was based on a mix of patients with and without cancer, which 
may explain the different findings in our study. In contrast, Australian researchers [7] showed almost perfect 
concordance between patient and GP for screen-detected and symptomatic presentation of colorectal 
cancer and breast cancer. This is consistent with our findings, except for colorectal cancer diagnosed through 
symptomatic presentation for which we found substantial agreement. The same study reported good 
concordance between patient and registry/specialist on date of diagnosis and date of treatment initiation, 
which was supported by our results. In line with our findings, two studies on breast cancer (one in China, one 
in Canada) reported substantial to almost perfect agreement on treatment initiation date, when comparing 
women’s answers with medical records [8],[12]. Our findings of high levels of agreement between patients 
and GPs on date of first presentation to primary care align with a Danish study on all newly diagnosed cancers 
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[10] and an Australian study on colorectal and breast cancer [7], although another Australian study on 
colorectal cancer found only moderate validity for this date [11]. 
 
4.3 Strengths and limitations 
A strength of our population-based cohort study is the large number of included patients (4,502 and 2,287). 
Moreover, the international context allowed data collection in eight jurisdictions with similar healthcare 
systems. The data on routes to diagnosis and milestone dates were collected from several different sources, 
including cancer registries and questionnaires completed by patients and their physicians (GP and SP). The 
ICBP4 surveys are based on state-of-the-art instruments, which undergo extensive translation and adaptation 
procedures, cognitive testing and pilot testing to ensure standardised high-quality data on routes to diagnosis 
and milestone dates [16]. The rich database allowed for multiple agreement analysis across several data 
sources and variables of interest. 
 
A limitation is the variation in some items across data sources used in the agreement analysis. For example, 
the date of diagnosis was defined by a single general definition in the patient questionnaire and in the 
registry, whereas this date had to be aggregated in the GP and SP questionnaires using different definitions 
(for example, date of histological confirmation, date of biopsy undertaken). Additionally, the treatment 
initiation date was based on a single definition in the questionnaire for SPs, whereas it was defined as the 
earliest date of either surgery, chemotherapy, radiology or other treatment in the patient questionnaire. 
Most likely, these issues have led to an underestimated agreement.  
 
Subtle differences between jurisdictions were observed in the understanding of ‘screening’ in the route to 
diagnosis. The patients did not always distinguish between screening and tests for symptom-based diagnosis. 
For example, GPs in Australia and Canada may use faecal occult blood testing (FOBT) for screening during 
consultations, whereas this is rare in the UK and Scandinavia. To counter these inconsistencies, we did not 
include screening data in the analysis if not specified whether it formed part of a national screening 
programme or was requested by the GP. 
 
If two dates for the same milestone differed by more than one year between different sources, this patient 
was excluded. This approach was taken to as a precaution against severe recall bias and potential 
misclassifications. Selection bias cannot be ruled out. However, as it accounted for only 3% of the possible 
cases (Figure 1), this cannot explain the high level of agreement found.  
 
A key limitation, as with many questionnaire-based studies, was the low patient participation rate. About 
three quarters of eligible patients was contacted, and one third of these completed a questionnaire. This may 
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have led to selection and non-response bias and has implications for interpretation and generalisation of 
findings. The analyses were undertaken using a complete case approach, leading to a lower response rate, 
especially in the analysis of dates. However, the sensitivity analysis confirmed the robustness of the results 
against missing data. Furthermore, the basic characteristics of excluded and included patients were broadly 
similar. 
 
 The ICBP4 recruitment process required the patient to be alive for at least 3-4 months after diagnosis; for 
some, up to 9 months after diagnosis. This may have led to recall bias and thus possibly underestimated 
agreement. Also, bias is conceivable as the study didn’t include those who experienced dying soon after 
diagnosis. These may be patients who had fast (‘sick-quick’ patients) or prolonged pathways leading to 
advanced stages. Some jurisdictions did not provide all necessary data from the registries and SP 
questionnaires, which may have caused selection bias. Moreover, the study included data from GP 
questionnaires, which might have induced selection bias if the non-responding GPs had a different perception 
of routes to diagnosis and index dates than the responding GPs. 
 
The broad international setting may hold other differences between jurisdictions that were not captured. 
Nevertheless, the clinical features of the participants were similar across cancer types and jurisdictions. The 
sample size was not sufficient to perform analyses at the level of each jurisdiction.  
 
4.4 Interpretation and implications 
The presented results have implications for research and development using data on the cancer pathway. 
The findings suggest that combining data from patient/physician questionnaires and nationwide registries 
can be useful to measure routes to diagnosis and milestone dates. For instance, patient questionnaires can 
be used when registry data and physician’s records do not include data on initial presentation. The present 
ICBP4 study illustrates that triangulation of data from multiple sources can provide more complete and 
reliable information on the pathways. To prioritise data sources, we developed hierarchical data rules [24]. 
We recommend application of similar hierarchical data rules in future projects, and the applied rules should 
be made publicly available to ease interpretation.  
 
Our findings of good agreement on milestone dates across all data sources and explored types of dates 
suggest that e.g. patient-reported data could complement cancer registration with patient reported date of 
first presentation to health care due to symptoms. The increasing use of patient-reported outcome measures 
(PROMs) in cancer care shows promising results, especially within clinical care [25],[26],[27]. Thus, one way 
to complement cancer registrations could be to routinely collect PROMs at specific time points [26],[28]. 
Routine PROM data on milestone dates could also supply public health authorities and clinicians with new 
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and valuable information on the real timeliness of a cancer diagnosis. This information may serve as an 
indicator of the responsiveness of the healthcare system when new initiatives are implemented (e.g. to 




We found adequate agreement between patient/physician questionnaires and registry data on routes to 
cancer diagnosis (screening, symptomatic presentation and other presentation) and milestone dates (date 
of first presentation to primary care, date of diagnosis and date of treatment initiation). The agreement on 
routes to diagnosis was generally higher for breast cancer than for colorectal, ovarian and lung cancers. The 
agreement on date of first presentation to primary care and date of treatment initiation was generally lower 
than the agreement on date of diagnosis. 
 
Our results suggest that combining data from patient/physician questionnaires and from registries may lead 
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Table A.1. Patients included in the analyses of routes to diagnosis (top) and milestone dates (bottom) in 
relation to identified patients  
 
 
Analysis of routes to diagnosis 
 
 Identified Included p-value 
 n (%) n (%)  
Gender       
Male 16416 (32,1) 1311 (29,2) <0.001 
Female 34801 (67,9) 3191 (70,9) 
Age group      
Under 40 219 (0,4) 0 (0,0)  
40-49 3882 (7,8) 381 (8,5) 
<0.001 
50-59 8602 (17,3) 941 (20,9) 
60-69 14284 (28,8) 1550 (34,4) 
70-79 14119 (28,4) 1168 (25,9) 
80-89 7593 (15,3) 435 (9,7) 
90+ 852 (1,7) 27 (0,6) 
Missing 114 (0,2) 0 (0,0) 
Dead at      
3 months 4083 (23,9) 0 (0,0) 
<0.001 6 months 3983 (23,3) 39 (14,1) 
9 months 4203 (24,6) 115 (41,5) 
12 months 4828 (28,2) 123 (44,4) 
Tumour stage1       
I 13039 (29,8) 1498 (33,3) 
<0.001 
II 10029 (22,9) 1186 (26,3) 
III 8730 (20,0) 1114 (24,7) 
IV 8996 (20,6) 527 (11,7) 
Missing 2921 (6,7) 177 (3,9) 
  
 
Analysis of milestone dates 
 
 Identified Included p-value 
 n (%) n (%)  
Gender       
Male 16416 (32,1) 582 (25,5) <0.001 
Female 34801 (67,9) 1705 (74,6) 
Age group      
Under 40 219 (0,4) 0 (0,0)  
40-49 3882 (7,8) 235 (10,3) 
<0.001 50-59 8602 (17,3) 495 (21,6) 
60-69 14284 (28,8) 806 (35,2) 
23 
 
70-79 14119 (28,4) 545 (23,8) 
80-89 7593 (15,3) 193 (8,4) 
90+ 852 (1,7) 13 (0,6) 
Missing 114 (0,2) 0 (0,0) 
Dead at      
3 months 4083 (23,9) 0 (0,0) 
<0.001 6 months 3983 (23,3) 12 (9,6) 
9 months 4203 (24,6) 60 (38,4) 
12 months 4828 (28,2) 125 (52,0) 
Tumour stage1       
I 13039 (29,8) 774 (33,8) 
<0.001 
II 10029 (22,9) 672 (29,4) 
III 8730 (20,0) 554 (24,2) 
IV 8996 (20,6) 243 (10,6) 
Missing 2921 (6,7) 44 (1,9) 
1 TNM classification for breast and lung cancers, TNM or Duke’s classification for colorectal cancer, TNM or FIGO 
classification for ovarian cancer 
 
 
Table A.2. Basic characteristics of patients included in the analyses of routes to diagnosis (top) and 
milestone dates (bottom) (n and % if nothing else stated) for each jurisdiction 
Analysis of routes to diagnosis 
 
  Wales England Scotland N Ireland Denmark Ontario Manitoba Victoria 
Breast cancer (N=165) (N=224) (N=282) (N=249) (N=205) (N=160) (N=210) (N=78) 
Age (years), Median (IQI) 64 (53,70) 63 (55,70) 62 (54,70) 60 (51,70) 62 (54,70) 62 (55,68) 62 (53,70) 61 (52,66) 
Comorbidity1         
None 119 (72) 168 (75) 188 (67) 189 (76) 129 (63) 106 (66) 143 (68) 56 (72) 
Medium 45 (27) 54 (24) 89 (32) 56 (22) 76 (37) 47 (29) 65 (31) 22 (28) 
High 1 (0.6) 1 (1) 4 (1) 3 (1) 0 (0) 0 (0) 2 (1) 0 (0) 
Missing  0 (0) 1 (1) 1 (1) 1 (1) 0(0) 7 (4) 0 (0) 0 (0) 
 
Colorectal cancer (N=167) (N=174) (N=212) (N=205) (N=203) (N=116) (N=133) (N=191) 
Age (years), median (IQI) 71 (65,77) 70 (65,77) 69 (61,77) 67 (60,74) 70 (65,77) 68 (60,76) 69 (61,76) 66 (57,75) 
Gender, male 103 (62) 101 (58) 122 (58) 121 (59) 118 (58) 71 (61) 71 (53) 109 (57) 
Comorbidity1         
None 83 (50) 90 (52) 118 (56) 110 (54) 102 (50) 73 (63) 81 (61) 113 (59) 
Medium 78 (47) 77 (44) 93 (44) 92 (45) 98 (47) 40 (34) 50 (38) 72 (38) 
High 6 (4) 7 (4) 1 (1) 3 (1) 6 (3) 3 (3) 2 (2) 5 (3) 
Missing  0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 1 (1) 
 
Lung cancer (N=77) (N=146) (N=137) (N=141) (N=154) (N=86) (N=96) (N=102) 
Age (years), median (IQI) 69 (64,74) 71 (65,76) 69 (64,76) 69 (63,74) 68 (62,74) 70 (65,75) 71 (64,77) 69 (63,73) 
Gender, male 41 (53) 76 (52) 80 (58) 77 (55) 76 (49) 44 (51) 43 (45) 58 (57) 
Comorbidity1         
None 32 (42) 61 (42) 56 (41) 52 (37) 53 (34) 27 (31) 37 (39) 37 (36) 
Medium 44 (57) 79 (54) 73 (53) 78 (55) 93 (60) 51 (59) 54 (56) 60 (59) 
High 1 (1) 6 (4) 8 (6) 11 (8) 8 (5) 8 (9) 5 (5) 5 (5) 
 
Ovarian cancer (N=41) (N=112) (N=68) (N=61) (N=169) (N=31) (N=35) (N=72) 
24 
 
Age (years), median (IQI) 62 (56,72) 64 (56,71) 63 (54,72) 63 (56,70) 66 (56,73) 60 (55,70) 61 (56,70) 61 (53,68) 
Comorbidity1         
None 25 (61) 81 (72) 50 (74) 48 (79) 110 (65) 20 (65) 21 (60) 53 (74) 
Medium 16 (39) 30 (27) 16 (24) 13 (21) 59 (35) 10 (32) 13 (37) 19 (26) 
High 0 (0) 1 (1) 2 (3) 0 (0) 0 (0) 1 (3) 1 (3) 0 (0) 
 
Analysis of milestone dates 
  Wales England Scotland N Ireland Denmark Ontario Manitoba Victoria 
Breast cancer (N=115) (N=158) (N=148) (N=189) (N=91) (N=45) (N=173) (N=89) 
Age (years), median (IQI) 64 (53,72) 63 (53,70) 62 (53,73) 59 (51,68) 63 (52,69) 62 (55,69) 62 (53,68) 57 (51,67) 
Comorbidity1         
None 81 (70) 120 (76) 99 (67) 142 (75) 56 (62) 29 (64) 119 (69) 62 (70) 
Medium 32 (28) 37 (23) 45 (30) 44 (23) 34 (37) 15 (33) 53 (31) 27 (30) 
High 2 (2) 0 (0) 4 (3) 2 (1) 1 (1) 0 (0) 1 (1) 0 (0) 
Missing  0 (0) 1 (1) 0 (0) 1 (1) 0(0) 1 (2) 0 (0) 0 (0) 
 
Colorectal cancer (N=97) (N=88) (N=106) (N=127) (N=87) (N=23) (N=86) (N=50) 
Age (years), median (IQI) 68 (62,76) 71 (64,80) 68 (60,76) 67 (61,73) 70 (65,76) 71 (62,80) 67 (57,75) 70 (60,76) 
Gender, male 56 (58) 57 (65) 66 (62) 73 (57) 52 (60) 12 (52) 53 (62) 31 (62) 
Comorbidity1         
None 53 (55) 48 (55) 59 (56) 62 (49) 42 (48) 12 (52) 57 (66) 27 (54) 
Medium 43 (44) 37 (42) 46 (43) 63 (50) 44 (51) 10 (43) 28 (33) 21 (42) 
High 1 (1) 3 (3) 1 (1) 2 (2) 1 (1) 1 (4) 1 (1) 2 (4) 
 
Lung cancer (N=45) (N=67) (N=45) (N=82) (N=54) (N=6) (N=46) (N=15) 
Age (years), median (IQI) 69 (64,75) 70 (65,75) 68 (64,78) 68 (61,74) 68 (63,73) 68 (64,71) 69 (64,77) 67 (60,79) 
Gender, male 29 (64) 31 (46) 27 (60) 41 (50) 28 (52) 3 (50) 15 (33) 8 (53) 
Comorbidity1         
None 16 (36) 25 (37) 22 (49) 33 (40) 24 (44) 2 (33) 23 (50) 6 (40) 
Medium 27 (60) 39 (58) 22 (49) 44 (54) 28 (52) 3 (50) 23 (50) 8 (53) 
High 2 (4) 3 (4) 1 (2) 5 (6) 2 (4) 1 (17) 0 (0) 1 (7) 
 
Ovarian cancer (N=29) (N=84) (N=30) (N=40) (N=15) (N=7) (N=21) (N=29) 
Age (years), median (IQI) 61 (58,71) 63 (56,72) 63 (50,69) 65 (56,71) 69 (49,77) 63 (52,68) 64 (56,70) 61 (53,65) 
Comorbidity1         
None 17 (59) 61 (73) 24 (80) 31 (78) 9 (60) 6 (86) 13 (62) 22 (76) 
Medium 12 (41) 22 (26) 6 (20) 9 (23) 6 (40) 1 (14) 8 (38) 7 (24) 
High 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
1Comorbidity coded as none (none reported), medium (1-2 reported) and high (3+ reported)   





Table A.3. Sensitivity analysis exploring the implications of including patients for whom not all data sources 
reported status for all types of routes to diagnosis. 
 Agreement between different data sources as to whether a cancer case was presented through screening, 
symptomatic or other route for each type of cancer. 
Route to 
diagnosis 
Data sources Overall agreement 
(%) 
Kappa (95%CI) AC1 (95%CI) 
Breast cancer         
Screening 
Patient vs GP (n=1766) 93 0.85(0.83-0.88) 0.86(0.84-0.88) 
Registry vs Patient (n=2046) 93 0.85(0.83-0.88) 0.85(0.83-0.88) 
Registry vs  GP (n=1449) 94 0.89(0.86-0.91) 0.89(0.87-0.92) 
     
Symptomatic Patient vs GP (n=1766) 93 0.87(0.85-0.89) 0.87(0.85-0.89) 
     
Other Patient vs GP (n=1766) 91 0.16(0.08-0.24)  0.91(0.89-0.92) 
Colorectal 
cancer         
Screening 
Patient vs GP (n=1287) 90 0.71(0.66-0.75) 0.85(0.82-0.87) 
Registry vs Patient (n=1031) 91 0.78(0.74-0.82) 0.86(0.83-0.89) 
Registry vs GP (n=910) 95 0.86(0.82-0.90) 0.93(0.91-0.95) 
     
Symptomatic Patient vs GP (n=1420) 84 0.61(0.56-0.66)  0.75(0.72-0.78)      
Other Patient vs GP (n=1420) 82 0.09(0.03-0.15)  0.78(0.75-0.81)  
Lung cancer         
Symptomatic Patient vs GP (n=940) 80 0.11(0.04-0.19)  0.74(0.70-0.78) 
     
Other Patient vs GP (n=939) 74 0.09(0.02-0.16) 0.65(0.60-0.69)  
Ovarian cancer         
Symptomatic Patient vs GP (n=589) 86 0.11(0.00-0.22) 0.84(0.80-0.88)      
Other Patient vs GP (n=589) 80 0.06(-0.03-0.15) 0.75(0.70-0.80) 
  Abbreviations: CI: confidence interval, GP=general practitioner 
 
 
Table A.4. Sensitivity analysis exploring the implications of including patients for whom not all data sources 
reported status for all types of dates. 
Mean difference (in days), proportions of agreement and concordance correlation coefficient (CCC) for dates 
of first visit to primary care, diagnosis and treatment shown for each type of cancer and all types combined. 
 












CCC (95% CI) 
Breast cancer             
First visit to PC* GP vs Patient (n=928)  -5.9  44 24 32 0.90 (0.89, 0.91)         
Diagnosis 
GP vs Patient (n=1790) 1.4 24 35 41 0.94 (0.93, 0.94)  
Registry  and Patient (n=2645)  -5.9 15 38 47 0.98 (0.98, 0.98) 
Registry and GP (n=1822) -5.7 27 39 34 0.97 (0.97, 0.97) 
SP and Registry (n=1001)  -4.9 17 61 23 0.99 (0.98, 0.99) 
SP  and Patient (n=989)  -1.0 16 49 35 0.93 (0.93, 0.94)  
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Treatment SP  and Patient (n=984) 2.4 62 15 23 0.89 (0.88, 0.90)  
 
Colorectal cancer             
First visit to PC* GP vs Patient (n=865) -3.2 24 20 56 0.89 (0.88, 0.91 )         
Diagnosis 
GP vs Patient (n=1462) 1.7 16 30 55 0.95 (0.94,0.95)  
Registry  and Patient (n=2133) -4.5  20 27 53 0.96 (0.96,0.96) 
Registry and GP (n=1517) -5.0 28 28 44 0.96 (0.96,0.97) 
SP and Registry (n=835) -5.1 19 51 30 0.96 (0.96,0.97) 
SP and Patient (n=813) -0.6 9 42 49 0.94 (0.93,0.95) 
Treatment SP  and Patient (n=785) 3.2 55 19 26 0.91 (0.90, 0.92)  
Lung cancer             
First visit to PC GP vs Patient (n=669)  0.03 18 19 64 0.90 (0.88, 0.91 ) 
       
Diagnosis 
GP vs Patient (n=1024) 11.9 8 22 69  0.93 (0.92, 0.94) 
Registry and Patient (n=1449) 4.0 4 21 74 0.96 (0.96,0.97) 
Registry  and GP (n=868) -9.9  23 25 53 0.96 (0.96,0.97) 
SP and Registry (n=452) -10.7 24 32 44 0.97 (0.96,0.97) 
 SP  and Patient (n=575) 7.7 5 30 65 0.93 (0.92,0.94)        
Treatment SP  and Patient (n=509) 2.4 45 24 31 0.94 (0.93,0.95) 
Ovarian cancer             
First visit to PC GP vs Patient (n=533) 5.0 36 20 44 0.91 (0.89, 0.92 )        
Diagnosis 
GP vs Patient (n=653) 4,9 9 26 65 0.92 (0.91,0.93) 
Registry and Patient (n=959) 7.0 7 23 70 0.95 (0.95,0.96) 
Registry  and GP (n=658) -2.2 20 24 56 0.95 (0.94,0.96) 
SP and Registry (n=332) -10.0 28 25 47 0.98 (0.97,0.98) 
 SP  and Patient (n=329) 5.3 7 30 63 0.96 (0.95,0.97) 
       
Treatment SP  and Patient (n=317) 7.2 53 18 29 0.90 (0.88,0.92)  
All cancers             
First visit to PC GP vs Patient  (n=2995) -1.9 31 21 48 0.90 (0.90,0.91)        
Diagnosis 
GP vs Patient (n=4929) 4.1 16 29 54 0.94 (0.94,0.94) 
Registry and Patient (n=7186) -1.8 13 29 57 0.97 (0.97,0.97) 
Registry  and GP (n=4865) -5.7 26 31 43 0.97 (0.96,0.97) 
SP and Registry (n=2620) -6.6 20 48 32 0.97 (0.97,0.98) 
 SP  and Patient (n=2706) 1.7 11 40 49 0.94 (0.94,0.94) 
       
Treatment SP  and Patient (n=2595) 3.2 56 18 26 0.91 (0.90,0.92)  
*only for symptomatic patients 




Table A.5. Basic characteristics of patients excluded and included in the analyses of routes to diagnosis 
(top) and milestone dates (bottom) (n and % if nothing else stated) 
Analysis of routes to diagnosis 
  
Excluded 
(if at least one diagnostic 
route was missing)       Included 
 
 
   p-value 
  (N=3,431)       (N=4,502)  
Age (years), Median (IQI) 67 (58,75) 
         
66 (58,74) 
 
  0.0181 
Gender, Male, 
 among colorectal and lung cancer 
patients 956 (54) 1,311 (56) 
 
  0.1792 
Comorbidity3          
None 2,193 (64) 2,630 (58)   <0.0012 
Medium 1,055 (31) 1,761 (39)  
High 46 (1) 99 (2)  
Missing  137 (4) 12 (1)  
 
Analysis of milestone dates 
  
Excluded 
(if at least one date 
 was missing)       Included 
 
 
   p-value 
  (N=5,390)       (N=2,287)  
Age (years), Median (IQI) 67 (59,75) 
         
65 (57,73) 
 
  <0.0011 
Gender, Male, 
 among colorectal and lung cancer 
patients 1609 (55) 582 (57) 
 
  0.2472 
Comorbidity3          
None 3277 (61) 1402 (61)   0.3582 
Medium 1868 (35) 844 (37)  
High 105 (2) 38 (2)  
Missing  140 (3) 3 (1)  
1 Mann-Whitney U test 
2 Pearson’s Chi2 test 
1Comorbidity coded as none (none reported), medium (1-2 reported) and high (3+ reported) 
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